CareDx, Inc.
CDNAStock
$40.34+56.50%52W
Market Cap$1.54B
P/E18.34x
Div yield—
Beta2.49
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)47.95%
Price vs S&P 500 (4W)27.36%
VGM Score62.39
Market Capitalization$1.54B
P/E Ratio (Annual)18.34x
Earnings Surprise History
Q1 260.34est. 0.14
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
3.93
3.93
4.00
4.00
Industry Peers — Health Services(29)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CDNACareDx, Inc. | D | B | B | $40.34 |
| NTRANatera, Inc. Common Stock | F | A | B | $269.83 |
| DGXQuest Diagnostics Inc. | C | D | C | $209.41 |
| LHLabcorp Holdings Inc. | C | D | C | $281.94 |
| GHGuardant Health, Inc. Common Stock | F | A | A | $155.00 |
| EXASExact Sciences Corp | F | B | B | $0.00 |
| BLLNBillionToOne, Inc. Class A Common Stock | F | F | B | $128.18 |
| RDNTRadNet, Inc. Common Stock | D | C | C | $62.99 |
| CAICaris Life Sciences, Inc. Common Stock | F | A | D | $16.48 |
| VCYTVeracyte, Inc. | D | A | A | $59.22 |
| CELCCelcuity Inc. Common Stock | — | — | B | $88.29 |
About
CareDx is a precision medicine company providing genomics-based testing solutions for transplant patients. Its primary products include AlloSure and AlloMap, diagnostic tests that monitor transplant function and rejection risk. The company generates most revenue from testing services in the United States, serving transplant recipients and caregivers throughout the patient journey.